방사성의약품 시장 : 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Radiopharmaceuticals Market was valued at USD 6.7 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% over the forecast period. This growth is primarily driven by the increasing prevalence of chronic diseases, rising demand for advanced diagnostic tools and treatments, and ongoing technological advancements in diagnostic imaging. Key imaging techniques like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) have significantly enhanced the accuracy of diagnostic processes, offering detailed functional and molecular insights that complement traditional anatomical imaging methods.

The demand for radiopharmaceuticals is further bolstered by their ability to improve diagnostic accuracy, enabling early detection and better management of chronic conditions such as cancer, cardiovascular diseases, and neurological disorders. As a result, there is a growing focus on developing radiotracers with improved sensitivity and specificity, which supports market expansion.

The overall radiopharmaceuticals industry is segregated based on Type, Radioisotope, Application, Source, End Use, and Region.

By type, the market is segmented into therapeutics and diagnostics, with diagnostics dominating the market at 72.6% in 2023. Radioisotopes such as Technetium-99m, Iodine-131, and Fluorine-18 are essential in imaging techniques like SPECT and PET, making them pivotal for diagnostic procedures across various medical fields.

Among radioisotopes, Technetium-99m holds the largest market share due to its favorable nuclear properties and versatility in forming stable radiopharmaceuticals for multiple diagnostic applications. The ability of this isotope to provide high-resolution imaging with minimal radiation exposure is a key factor contributing to its widespread use in medical imaging.

On the application front, the cancer segment is expected to see significant growth, driven by the increasing prevalence of cancer and the need for innovative diagnostics and therapies. Radiopharmaceuticals are increasingly used in cancer detection and treatment, making this segment a key driver of market growth.

The market is also segmented by source, with cyclotrons playing a crucial role due to their ability to produce various isotopes for immediate use, ensuring flexibility and safety in radiopharmaceutical production.

North America leads the global market, driven by the growing demand for advanced diagnostics and the proven clinical effectiveness of radiopharmaceuticals in improving patient outcomes. This region is expected to see robust growth during the forecast period.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic conditions
    • 3.2.1.2 Rising investments for novel cancer therapies
    • 3.2.1.3 Advancements in diagnostic imaging
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of therapies and diagnostic procedures
    • 3.2.2.2 Stringent government regulations
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Therapeutic
• 5.3 Diagnostics
  • 5.3.1 PET
  • 5.3.2 SPECT
  • 5.3.3 Other diagnostic tests

Chapter 6 Market Estimates and Forecast, By Radioisotopes, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Technetium 99m
• 6.3 Gallium 68
• 6.4 Lodine I
• 6.5 Fluorine 18
• 6.6 Copper 64
• 6.7 Radium 223
• 6.8 Zirconium 89
• 6.9 Other radioisotopes

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cancer
  • 7.2.1 Breast cancer
  • 7.2.2 Prostate cancer
  • 7.2.3 Lung cancer
  • 7.2.4 Other cancer types
• 7.3 Neurology
• 7.4 Cardiology
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Source, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Cyclotron
• 8.3 Nuclear reactors

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Diagnostic imaging centers
• 9.4 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Bayer AG
• 11.2 Bracco
• 11.3 Cardinal Health Inc.
• 11.4 Coqui Radiopharmaceuticals Corp
• 11.5 Curium Pharma
• 11.6 Eli Lilly and Company
• 11.7 General Electric Company
• 11.8 IRE ELiT
• 11.9 Iso-Tex Diagnostics, Inc
• 11.10 Jubilant Pharmova Limited
• 11.11 Lantheus
• 11.12 Novartis AG
• 11.13 SHINE Technologies, LLC
• 11.14 Telix Pharmaceuticals Limited